Clinical Trial Update: Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance [Phase 3]

View source ↗

Summary

Phase 3 randomized, placebo-controlled study evaluating extended-release GSK1838262 for Restless Legs Syndrome and associated sleep disturbance; trial completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• GSK1838262 Extended Release Tablets (GSK1838262)

Snippet

Sponsor: XenoPort, Inc. | Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS) | Phase 3 | Status: COMPLETED | Results posted: 2011-05-18